证券代码：301367 证券简称：瑞迈特 公司持续保持较大规模的研发投入，并取得了丰厚的研发成 果。截至 2025 年 6 月 30 日，公司拥有 666 项国内有效专利，其 中国内发明专利 116 项、国内实用新型专利 404 项、国内外观设 计专利 146 项；海外授权专利共计 266 项，其中包括美国专利 45 项、欧洲专利 38 项、欧盟外观专利 63 项、土耳其专利 20 项、日 本专利 22 项、澳大利亚专利 6 项、印度专利 18 项。 二、提问环节 1、对于美国市场，公司新无噪音棉呼吸机的销售推进情况 与市场表现。 新无噪音棉呼吸机于自 7 月开始已经批量进入美国市场，第 三季度美国 RH 的动销水平逐月提升明显，随着新呼吸机医疗报 销码的取得，后续放量较第三季度会相对明显。 北京瑞迈特医疗科技股份有限公司 投资者关系活动记录表 编号：2025—018 | □ | 特定对象调研 分析师会议 □ | | --- | --- | | 投资者关系活动 □ | 媒体采访 业绩说明会（电话形式） □ | | 类别 □ | 新闻发布会 √ 路演活动 | | □ | 现场参观 | | □ | 其他 | | ...

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The first CPAP sleep breathing machine was released in 2007, and the company received CE certification in 2008 and FDA certification in 2012. The company successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2][3] - The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering the entire cycle from diagnosis to treatment and chronic disease management. It is a leading enterprise in home non-invasive ventilators and masks in China, being the first domestic company to have non-invasive ventilator products certified by the FDA [2][3] Product and R&D Highlights - As of June 30, 2025, the company holds 666 valid domestic patents, including 116 invention patents, 404 utility model patents, and 146 design patents. It also has 266 overseas authorized patents, including 45 in the U.S. and 38 in Europe [3] - The main products include home non-invasive ventilators, ventilation masks, sleep monitors, high-flow humidified oxygen therapy devices, and oxygen concentrators, along with chronic disease management services [2][3] Sales and Market Strategy - The company initiated a shift from online distribution to direct sales at the end of September, with expectations for improved gross margins in the e-commerce sector starting in Q4 2025. This transition is anticipated to contribute positively to net profits [4] - The new noise-reducing ventilator has been entering the U.S. market since July, with significant sales growth observed in Q3. The acquisition of a medical reimbursement code is expected to further enhance sales volume [4] European Market Development - The European cloud platform has successfully integrated over a thousand primary and secondary agents. This integration is expected to facilitate the transition from non-mainstream to mainstream medical insurance markets, providing ongoing growth momentum in Europe [5] Investment and Technology Focus - The company has invested in Shenzhen Deda Xing Drive Technology Co., Ltd., a leading provider of precision motors and solutions, which aligns with the company's long-term strategic direction and enhances its core competitiveness [7] - The company is actively exploring the potential of AI technology in healthcare, focusing on integrating AI with core medical services to improve efficiency and optimize equipment performance [7]